S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
NASDAQ:ACRS

Aclaris Therapeutics - ACRS Stock Forecast, Price & News

$17.65
-0.35 (-1.94%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$17.46
$18.37
50-Day Range
$12.79
$18.00
52-Week Range
$9.26
$19.97
Volume
438,710 shs
Average Volume
446,496 shs
Market Capitalization
$1.18 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.00

Aclaris Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
115.3% Upside
$38.00 Price Target
Short Interest
Bearish
5.83% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.59mentions of Aclaris Therapeutics in the last 14 days
Based on 20 Articles This Week
Insider Trading
Selling Shares
$296,214 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.49) to ($1.50) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

836th out of 1,098 stocks

Pharmaceutical Preparations Industry

408th out of 536 stocks

ACRS stock logo

About Aclaris Therapeutics (NASDAQ:ACRS) Stock

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Aclaris Therapeutics Trading Down 1.4 %

Shares of NASDAQ:ACRS traded down $0.25 during midday trading on Tuesday, hitting $17.75. The company's stock had a trading volume of 18,134 shares, compared to its average volume of 251,547. The business's 50 day moving average is $15.14 and its two-hundred day moving average is $14.40. Aclaris Therapeutics has a 12-month low of $9.26 and a 12-month high of $19.97.

Aclaris Therapeutics (NASDAQ:ACRS - Get Rating) last issued its quarterly earnings results on Wednesday, August 3rd. The biotechnology company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.05. Aclaris Therapeutics had a negative return on equity of 40.14% and a negative net margin of 1,355.98%. On average, sell-side analysts expect that Aclaris Therapeutics will post -1.49 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on ACRS shares. William Blair reaffirmed an "outperform" rating on shares of Aclaris Therapeutics in a research note on Wednesday, May 11th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Aclaris Therapeutics in a research note on Monday, August 1st. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $38.00.

Insiders Place Their Bets

In other Aclaris Therapeutics news, Director Andrew N. Schiff sold 19,565 shares of the firm's stock in a transaction on Friday, June 17th. The stock was sold at an average price of $15.14, for a total transaction of $296,214.10. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 6.70% of the stock is currently owned by company insiders.

Receive ACRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACRS Stock News Headlines

Aclaris Therapeutics Tops Q1 EPS by 9c
Aclaris Therapeutics Q1 2022 Earnings Preview
Aclaris falls on the exit of medical chief
See More Headlines
Receive ACRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACRS Company Calendar

Last Earnings
8/03/2022
Today
8/09/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACRS
Employees
72
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$38.00
High Stock Price Forecast
$50.00
Low Stock Price Forecast
$26.00
Forecasted Upside/Downside
+115.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-90,860,000.00
Net Margins
-1,355.98%
Pretax Margin
-1,355.98%

Debt

Sales & Book Value

Annual Sales
$6.76 million
Book Value
$3.22 per share

Miscellaneous

Free Float
62,205,000
Market Cap
$1.18 billion
Optionable
Optionable
Beta
0.60














ACRS Stock - Frequently Asked Questions

Should I buy or sell Aclaris Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACRS shares.
View ACRS analyst ratings
or view top-rated stocks.

What is Aclaris Therapeutics' stock price forecast for 2022?

4 equities research analysts have issued 12 month price objectives for Aclaris Therapeutics' stock. Their ACRS share price forecasts range from $26.00 to $50.00. On average, they expect the company's share price to reach $38.00 in the next twelve months. This suggests a possible upside of 113.4% from the stock's current price.
View analysts price targets for ACRS
or view top-rated stocks among Wall Street analysts.

How has Aclaris Therapeutics' stock performed in 2022?

Aclaris Therapeutics' stock was trading at $14.54 at the start of the year. Since then, ACRS shares have increased by 22.5% and is now trading at $17.81.
View the best growth stocks for 2022 here
.

When is Aclaris Therapeutics' next earnings date?

Aclaris Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our ACRS earnings forecast
.

How were Aclaris Therapeutics' earnings last quarter?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) issued its quarterly earnings data on Wednesday, August, 3rd. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.05. Aclaris Therapeutics had a negative trailing twelve-month return on equity of 40.14% and a negative net margin of 1,355.98%.

What is Neal Walker's approval rating as Aclaris Therapeutics' CEO?

1 employees have rated Aclaris Therapeutics Chief Executive Officer Neal Walker on Glassdoor.com. Neal Walker has an approval rating of 100% among the company's employees. This puts Neal Walker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Aclaris Therapeutics own?

What is Aclaris Therapeutics' stock symbol?

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

Who are Aclaris Therapeutics' major shareholders?

Aclaris Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Silverarc Capital Management LLC (0.81%), Assenagon Asset Management S.A. (0.44%), Integral Health Asset Management LLC (0.43%), Swiss National Bank (0.15%), Requisite Capital Management LLC (0.07%) and State Board of Administration of Florida Retirement System (0.03%). Insiders that own company stock include Andrew N Schiff, David N Gordon, Frank Ruffo, Joseph Monahan, Kamil Ali-Jackson and Neal Walker.
View institutional ownership trends
.

How do I buy shares of Aclaris Therapeutics?

Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aclaris Therapeutics' stock price today?

One share of ACRS stock can currently be purchased for approximately $17.81.

How much money does Aclaris Therapeutics make?

Aclaris Therapeutics (NASDAQ:ACRS) has a market capitalization of $1.19 billion and generates $6.76 million in revenue each year. The biotechnology company earns $-90,860,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis.

How many employees does Aclaris Therapeutics have?

Aclaris Therapeutics employs 72 workers across the globe.

How can I contact Aclaris Therapeutics?

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The official website for the company is www.aclaristx.com. The biotechnology company can be reached via phone at (484) 324-7933, via email at investors@aclaristx.com, or via fax at 484-320-2344.

This page (NASDAQ:ACRS) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.